excited Tricia. to in like back share and far XXXX. take I'm you here progress But a you, to begin, at our so remind I'd why we're Thank GeneDx. step
massive the a conversion to from testing panels. Over multi-gene decade, we've past single-gene seen
pioneering With more the GeneDx versus comprehensive played also whole role in conversion poised in clinical lead era, supporting has more this GeneDx set services ushering comprehensive, exome is answers more to instrumental to deliver more of an data this necessity definitive exome patients. more to testing. now genome an whole new of panels, with sequencing even while and multi-gene
Today, we're focused disease on the testing pediatric setting. and rare
lack a generally of care a current diagnostic for for With and children is multiyear usually of in resulting the odyssey standard testing, their parents.
rare average, that know years diseases And eight that on We a all a takes when genome from weeks. to diagnose fact that it In we shortens dramatically taken are not exome disease. and timeframe to as whole. also pediatric-rare testing, these at years rare know
disease XX of cancer. as actually be half as nearly eight with women Consider are are that in Similarly, Think in hundreds rare whom have cancer children. will there cancer. people that together a X,XXX a of, is breast constellation of are common one how Of of one diseases diseases. diagnosed rare
And million in or not U.S. fortunately, each genome we one fact, estimate from to mission testing. alone the benefit over children In infants whole expand year we're in would that our alone care. and exome
given and as major the and/or whole exome highly the genome are a and whole validated test Medical genome exome societies, Society such are as first-line cover moving for ACMG, NSGC Epilepsy payers testing, American national sequencing to costly and alternative. calling
over tested is past has completed Of of the year. in building. past a XXX,XXX Momentum have exomes quarter just decade GeneDx been the them the
genome exome and become we neurodegenerative increasingly the us expect to population. whole disease we allowing patients standard tests cardiovascular will that of diseases future, expand to look with the broader into as, As such adult and care for
utilization to job of services, number is as today, primarily converting on panel an as serve testing well But one testing. as that with expanding pediatric physicians' of stepping the our emphasis use in exome tests stones exome
patients genetic market in XXXX quarter our generated into that, in over the let's pleased physicians our coming So and XX,XXX I us say to first We growing. we've revenue are increased of more nearly And and turning at in more. volume GeneDx this saw $XX is across testing of tests am confidence dive that million testing to quarter, giving XXXX. progress. all and the
growth focus on gives accelerating the volume all and will QX test strategy from to The working, exome is conviction our QX revenue the that is gains into us the in lines of growth. materialize these Furthermore, working. the use
of which revenues in exome increase test, of and genome exome a reflected million full $XX.X year-over-year volume $XX Our the revenue, is million delivered first progress quarter. increase in revenues and the whole in robust of the representing in XX%
our We deliver in course of and revenue this these as throughout see expect approximately April, gross volume momentum continue year XX%. the we to to a of see expansion tests the of exome growth in margin and margin
in this ordering to towards margin a build shift and from that frame the are second factors see amount quarter enable will time growth recognition, this to expect of results revenue revenue There half we the five in year. and second acceleration. significant gross the Given of
continuing strengthen our strategy. First, footprint commercial we're to and
patients our important as them as certain of and Our team volume includes broader testing. genetic that This see better to We physicians stones is increased the tests are to exome. on strategically for non-exome focused physicians converting with become comfortable are stepping business. tests that better for
We're are diagnostics. encouraged exome genetic were testing ordered nongenetics, GeneDx. to a that patients tests by We're and We in behind. which GeneDx their yield customers panels, data educating that multi-gene leave physicians first who exome QX to compared of new CMA, also new clinicians provides higher who like that show be FMRX, diagnostic many may targeting to XX%
taken orders invest among higher year sequencing. sales incentive We And orders first and year. support our for commercial to dedicated XX also the in of includes client team. from were growth. sales teammates added our last to XX test drive the We've and to We've rep medical and from part to United specialists continue care the neurologists expanded That across team. to pediatric significantly each to States managers, territories our managed to cross-functional conversion science the also Leason, built relationship panel exome of compared plans
marketing. is acceleration our in Second,
engagement meeting generating ultimately increasing data are at variety and clinic. aid initiatives of efforts, brand and to conferences, through them they Our and launching talking in team clinician in growth. awareness accelerate of the share where in publications, focused the on is to and build We're a QX education, outside
we Our differentiation cross-channel GeneDx's as through from and to QX continue others to recognition the in offerings website e-mail to and we awareness that. traffic market. activities campaigns drive expect on to our social advertising, and doubled XXXX, fact, And of brand expand bringing and presence build since media we've build
providing patients. CMA. which sequencing the exome exome data much more X,XXX Annual covers of data showed and poster, CNVs, to and the diagnostic a CMA Third, than the patients new exome into or that recently to detecting who we sequencing sequencing had demonstrated CNV. compared is yield sequence only where variance recorded CNVs, or as as copy exome in CMA both on higher number microarray variants it clinical we're for Meeting, We continuing limited to research, which ACMG at insightful presented over chromosomal sequencing value diagnostic of And is the contribute advantages also
outdated guidelines CMA and is exome why less a adoption presented current used commonly care research at these driven and to critical time. data that driving ACMG takes guiding is conversations are convince a clinicians first. test standard our should order Sharing by they of
focus We've collection for has automate sequencing, time efficiency. to option, rapid COGS been experience product patients Fourth decreasing which rate relative our Trio improve on swab genome shown including facilitate our for parental is enables by or samples quality. our for Buckle key turnaround also collection the results gross margins. been diagnosis and customer with increase and Automation double. is and the quicker of testing, easier to nearly high our introduced to testing shorten which expanded We've to working to same improvement also operating our
goes The our fifth beyond own efforts. factor
amplified genome with sequencing. aware and and notice in taking societies the sequencing are policy payers of adopted medical be these of Cigna are they UnitedHealthcare benefits and working are work of sure by who and exome particular, health-economic Both changes. have recently Our favorable physicians to of is we clinical genome coverage and favorable
do Recently, state coverage to and XXth are state an published sequencing make updated coverage so. Carolina exome clinical North Medicaid meaningful for the outpatient to continuing becoming policy to coverage setting add progress. groups
do to barriers One the of many with results. key testing what to of the adoption is the
step so to further advocacy relief. many, patients best help And answer a possible getting groups to an and connect we're a payers by them. with a working ecosystem the broader committed For to for as treatment of biopharma, going
opportunity with our biopharma of across Our based are Centrella seeing flow deal which therapeutic the clinical We're data and significant. genomic is on various partner generated areas part to assets, platform.
including quarter, on groups. data we first with signed the or focused neurological diseases In forming rare disorders, agreements companies five
product these are Centralis scalable a internal partners have with patients We efficiently data gross We agreements deliver gather as Data teams value our margins helps believe more highly launched called also well. these which Explorer, and and new high our opportunities. high to and
to discovery way in our improve health direct reach drug exciting in personalized XXXX. moment delivery care actionable We're treatment and profitability to on an of to we're year-to-date performance strong the accelerate inform in diagnosis With development. clearly and and health insights
Kevin. pass the with to call that, to like And I'd
